Rapid Diagnosis of Smear-negative Tuberculosis by Bronchoalveolar Lavage Enzyme-linked Immunospot

Transcription

1 Rapid Diagnosis of Smear-negative Tuberculosis by Bronchoalveolar Lavage Enzyme-linked Immunospot Claudia Jafari, Martin Ernst, Barbara Kalsdorf, Ulf Greinert, Roland Diel, Detlef Kirsten, Kathleen Marienfeld, Ajit Lalvani, and Christoph Lange Division of Clinical Infectious Diseases and Division of Immune Cell Analytics, Research Center Borstel, Borstel; Department of Public Health, University of Düsseldorf, Düsseldorf; Center for Pulmonary Medicine and Thoracic Surgery, Hospital Großhansdorf, Großhansdorf, Germany; and Tuberculosis Immunology Group, Nuffield Department of Clinical Medicine, John Radcliff Hospital, University of Oxford, Oxford, United Kingdom Rationale: In a large proportion of patients with active pulmonary tuberculosis (ptb), acid-fast bacilli smear results for sputum and bronchial secretions are negative. Detectable growth of Mycobacterium tuberculosis (MTB) in cultures takes several weeks and MTBspecific DNA amplification results on sputum and bronchial secretions are variable in these patients. Objective: We investigated whether a rapid diagnosis of ptb can be established by enumeration of MTB-specific mononuclear cells from bronchoalveolar lavage (BAL) fluid in routine clinical practice. Methods: Patients presenting to a tertiary hospital with medical histories and pulmonary infiltrates compatible with tuberculosis, and negative acid-fast bacilli smear results (three) from sputum, were prospectively enrolled in this study. An MTB-specific enzymelinked immunospot assay (ELISPOT [T-SPOT.TB; Oxford Immunotec, Abingdon, UK]) with early antigenic target-6 (ESAT-6) and culture filtrate protein-10 (CFP-10) peptides was performed on peripheral blood mononuclear cells (PBMCs) and mononuclear cells from the BAL fluid (BALMCs). Measurements and Main Results: Of 37 patients, 12 were found to have smear-negative ptb and 25 were found to have an alternative diagnosis. Patients with tuberculosis had a median number of 17 ESAT-6 specific cells and 24.5 CFP-10 specific cells per 200,000 PBMCs and 37.5 ESAT-6 specific cells and 49.5 CFP-10 specific cells per 200,000 cells in the BAL fluid. Control patients had a median of 1 ESAT-6 specific cell and 1 CFP-10 specific cell per 200,000 PBMCs and no ESAT-6 and CFP-10 specific cells per 200,000 cells in the BAL fluid (p ). All patients with TB but none of the control subjects had more than 5 spot-forming cells per 200,000 BALMCs with either peptide in the BAL fluid ELISPOT. Conclusion: Smear-negative pulmonary tuberculosis can be diagnosed rapidly by identification of MTB-specific cells in the BAL fluid. Keywords: bronchoalveolar lavage; CFP-10; ELISPOT; ESAT-6; tuberculosis Tuberculosis (TB) is one of the leading causes of morbidity and mortality worldwide, affecting more than 8 million persons annually (1), mostly with pulmonary tuberculosis (ptb). Confirmation of the presumptive diagnosis of tuberculosis is usually delayed, as detection of growth of Mycobacterium tuberculosis (MTB) in liquid or solid medium takes an average of 2 wk of culture (2). However, only 72% of cases of pulmonary tuberculosis in Germany were culture positive in 2003 (3). The rapid (Received in original form April 3, 2006; accepted in final form July 19, 2006 ) Supported by the H.W. and J. Hector Foundation (C.L.). A.L. is a Wellcome Senior Research Fellow in Clinical Sciences. Correspondence and requests for reprints should be addressed to Christoph Lange, M.D., Ph.D., Division of Clinical Infectious Diseases, Research Center Borstel, Parkallee 35, Borstel, Germany. clange@fz-borstel.de Am J Respir Crit Care Med Vol 174. pp , 2006 Originally Published in Press as DOI: /rccm OC on July 20, 2006 Internet address: diagnosis of pulmonary tuberculosis relies therefore on clinical symptoms and radiologic findings, and on the detection of acid/ alcohol-fast bacilli (AFB) in sputum or bronchial secretions. Detection of MTB-specific gene sequences in respiratory specimens by DNA amplification may rapidly confirm the diagnosis of ptb, but DNA amplification for the diagnosis of tuberculosis is not standardized and is available only in specialized institutions. The sensitivity of sputum or bronchoalveolar lavage (BAL) microscopy for the detection of AFB is variable in ptb and ranges from 50 to 80% for three consecutive specimens (4). In patients with smear-negative ptb the sensitivity of sputum or BAL MTB-specific DNA amplification ranges from 48 to 80% (5). Thus, a substantial proportion of patients with ptb remain undiagnosed by current laboratory techniques until results of MTB cultures become available. Enzyme-linked immunospot (ELISPOT) and enzyme-linked immunoassay (ELISA) techniques have been developed to rapidly detect IFN- production by MTB-specific peripheral blood mononuclear cells (PBMCs) for the diagnosis of MTB infection. These assays use peptides from early antigenic target-6 (ESAT-6) and culture filtrate protein-10 (CFP-10), which are encoded by the region of difference-1 (RD-1) in the MTB genome, a region that is absent from all strains of Mycobacterium bovis bacille Calmette-Guérin (BCG) vaccine and most nontuberculous mycobacteria (6 9). The sensitivity of these tests in active TB ranges from 76 to 100% (9 17) whereas the specificity exceeds 88% (9, 14 16, 18). In TB contact tracing, these tests are a better indicator of close exposure to an index case than the tuberculin skin test (TST) (19 23). Although these tests are unaffected by prior BCG vaccination, they cannot distinguish between active and latent TB when performed on PBMCs (reviewed by Dheda and coworkers [24] and Pai and coworkers [25]). Approximately 95 to 98% of T lymphocytes are confined to lymphatic organs (26). In tuberculosis, MTB-specific T cells clonally expand and are recruited to the site of infection (27, 28). In persons with pulmonary tuberculosis MTB-specific T cells should therefore be detectable among mononuclear cells derived by BAL of the affected pulmonary segment. In patients with suspected tuberculosis and smear-negative microscopy, bronchoscopy with BAL is a safe procedure when guidelines are followed and may be indicated to exclude other diseases such as bronchogenic carcinoma or sarcoidosis (29, 30). We therefore recruited consecutively all patients with a suspected diagnosis of ptb and smear-negative sputum microscopy and studied prospectively whether patients with smear-negative ptb can be detected rapidly by enumeration of ESAT-6 and CFP-10 specific IFN- producing T cells from BAL fluid. To our knowledge, this is the first prospective trial in routine practice to evaluate whether active ptb can be distinguished from latent TB infection (LTBI) by enumeration of MTBspecific T cells from the site of disease.

2 Jafari, Ernst, Kalsdorf, et al.: TB Diagnosis by BAL ELISPOT 1049 METHODS Patients After informed consent was obtained, patients with three negative AFB smear results on consecutive days, pulmonary infiltrates by chest X-ray or thoracic computed tomography (CT), and a medical history compatible with TB were enrolled at the Medical Clinic of the Research Center Borstel (Borstel, Germany) and the Hospital Großhansdorf (Großhansdorf, Germany). PBMCs were obtained by a venous blood draw of 30 ml for two-color flow cytometry and MTB-specific ELISPOT. Bronchoscopy was performed according to German guidelines (31) with transbronchial biopsies for histology and BAL with ml of normal saline from an affected lung segment for microbiological culture, MTB-specific DNA amplification (BD ProbeTec ET system; BD Diagnostic Systems, Sparks, MD), cytological differentiation, and BAL ELISPOT. Tuberculin skin testing was performed with 0.1 ml (2 TU) of tuberculin RT23 (Statens Serum Institut, Copenhagen, Denmark). The induration was measured after h, using the ballpoint technique (32). Test results for three initial sputum samples and sputum or BAL MTB-specific DNA amplification were obtained for 100 consecutive patients with culture-confirmed ptb at the Medical Clinic of the Research Center Borstel. The study was approved by the ethics committee of the University of Luebeck Medical School (Luebeck, Germany), and all patients gave written, informed consent. Immunophenotyping Lymphocyte subsets were enumerated in PBMCs obtained from freshly drawn blood and in cells from BAL fluid, using directly labeled murine monoclonal antibodies against CD3, CD4, CD8, CD45R0, CD45RA, HLA-DR, and CD38 (Dako, Hamburg, Germany) by two-color flow cytometry (FACSCalibur; Becton Dickinson, Heidelberg, Germany). Cell Cultures PBMCs were prepared by Ficoll-Hypaque density gradient centrifugation from heparinized blood. Single-cell suspensions from BAL fluid were obtained by passing the BAL fluid through a stainless steel sieve (WMF, Teesieb Profi Plus; WMF, Geislingen, Germany) with a mesh aperture of 0.5 mm. Cells were put into culture in RPMI 1640 medium containing penicillin (100 U/ml), streptomycin (100 g/ml), l-glutamine (2 mmol/l), and 5% fetal calf serum (culture medium). ELISPOT Assay ELISPOT assays for human IFN- were performed with test plates from the T-SPOT.TB test (Oxford Immunotec, Abingdon, UK). Briefly, 200,000 PBMCs and mononuclear cells from BAL fluid (BALMCs) were plated overnight on 96-well plates, which had been precoated with a mouse anti-human IFN- antibody, in 200 l of culture medium per well. The cells were left unstimulated (negative control) or were stimulated with anti-cd3 monoclonal antibody (clone X35, 10 ng/ml; Beckman Coulter, Krefeld, Germany; positive control), with purified protein derivative of tuberculin (PPD, 10 g/ml; Statens Serum Institut), or with ESAT-6 and CFP-10 peptides (5 g/ml; kindly provided by Oxford Immunotec). Culture of the plates, washing, counterstaining, visualization, and analysis of the spots were performed according to manufacturer guidelines. The response of stimulated cultures was considered positive when the test well contained at least five more spots and had twice the number of spots than the control well. The background number of spots in negative control wells was always less than five spots per well. Statistical Analysis All statistical tests were performed as exploratory analyses without adjustment for multiple testing, with nominal significance defined as p Continuous variables were compared by nonparametric testing (Mann-Whitney test) because the data were not normally distributed. RESULTS After informed consent was obtained, 37 patients with a suspected diagnosis of ptb were prospectively enrolled in this study. In eight of the patients, MTB was cultured from either sputum, BAL fluid, or both. In addition, four patients who presented with pulmonary infiltrates typical of TB on chest CT responded clinically and radiographically to anti-tb therapy and were given a final diagnosis of ptb (Table 1). Twenty-five patients with negative MTB cultures were diagnosed with etiologies other than TB, including sarcoidosis (n 4), pneumonia (n 6), bronchogenic carcinoma (n 4), former tuberculosis (n 7), cryptogenic organizing pneumonia (COP; n 3), septic embolism (n 1), rheumatoid arthritis (n 1), and former Mycobacterium kansasii infection with no recent activity (n 1). Two patients with a previous history of TB now presented with bronchogenic carcinoma without signs of TB reactivation. Patients with TB were younger (31.1 vs yr) when compared with patients with alternative diseases (Table 2). The median induration of the TST was 20 mm in the TB group and 0 mm in the non-tb group (Figure 1). Two patients (17%) in the TB group had a TST induration of 5 mm or less and 3 of 25 patients (12%) in the control group had a TST induration of 15 mm or more. The TST was not repeated in two patients with a previous history of TB. In the TB group. MTB-specific DNA amplification was positive only in the sputum of two patients, in the sputum and BAL fluid of one patient, and only in the BAL fluid of one patient. In the control group, two patients with pulmonary infiltrates due to bronchogenic carcinoma also had a positive MTB-specific DNA amplification result from BAL fluid. Both patients had a history of ptb in 1994 and 2005, respectively, and each was treated for 6 mo at that time. Taken together, MTB-specific DNA amplification was positive in 4 of 12 patients (33%) with TB (3 of 8 with cultureconfirmed TB; 38%) and also in the BAL fluid of 2 of 25 patients (8%) without active TB. In 100 patients (29 females and 71 males) with cultureconfirmed ptb identified retrospectively at our institution, AFB were seen on sputum microscopy in 44, 51, and 54 instances with the first, second, and third examined sputum sample, respectively. In 49 patients, MTB-specific DNA amplification was performed on sputum, bronchial secretion, or gastric aspirate. Positive results were found in 41 patients (84%) and in 18 of 25 patients (72%) with smear-negative TB. Of those 18 smearnegative patients with positive DNA amplification results, 11 were positive on sputum, 4 were positive on BAL, one was positive on gastric aspirate, and 2 had a positive result from a transbronchial biopsy specimen. Among the 37 prospectively recruited patients, all 12 patients with TB but none of the control subjects had more than five spot-forming cells per 200,000 BALMCs with either antigen in the BAL ELISPOT. Median ESAT-6 and CFP-10 specific ELISPOT responses (CFP-10 specific responses could not be performed in 3 of 25 patients from the control group because of a technical error) were higher in PBMCs (17.0 and 24.5) and BALMCs (37.5 and 49.5) from patients with TB versus control subjects (PBMCs, 1.0 and 1.0; BALMCs, 0 and 0; respectively; Table 1 and Figure 2). The sensitivity and specificity of the MTBspecific ELISPOT with ESAT-6 and CFP-10 peptides performed on BALMCs were both 100% for the diagnosis of active tuberculosis (95% confidence interval, ). When the ratio of IFN- spot-forming cells from BALMCs and PBMCs in response to MTB-specific peptides was calculated, patients with active TB had on average 9.6 times (p 0.001) more ESAT-6 specific T cells and 7.9 times (p 0.001) more

3 1050 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL TABLE 1. SYSTEMIC AND PULMONARY Mycobacterium tuberculosis SPECIFIC IMMUNE RESPONSES IN PATIENTS WITH PULMONARY TUBERCULOSIS AND PATIENTS WITH PULMONARY INFILTRATES OF DIFFERENT ORIGIN Number of Age Ethnic Country of TST Lobes ESAT-6* CFP-10* ESAT-6* CFP-10* No. (yr) Sex Origin Birth Diagnosis (mm) MTB Culture MTB NAT Involved (PBMCs) (PBMCs) (BALMCs (BALMCs) 1 29 M Asian Sri Lanka Active ptb 13 Pos (SPT, BAL) Pos (SPT, BAL) 2 2 (3 1) 40 (41 1) 44 (111 77) 200 (277 77) 2 37 M White Serbia Active ptb 4 Pos (BAL) Pos (BAL) 1 29 (29 0) 12 (12 0) 34 (34 0) 50 (50 0) 3 29 M White Dagestan Active ptb 15 Pos (SPT, BAL) Pos (SPT) 1 10 (10 0) 2 (2 0) 13 (36 23) 26 (49 23) 4 28 M Asian Afghanistan Active ptb 5 Neg Neg 1 24 (27 3) 30 (33 3) 61 (73 12) 73 (85 12) 5 22 M White Russia Active ptb 22 Pos (SPT) Neg 1 9 (9 0) 19 (19 0) 12 (13 1) 45 (46 1) 6 33 M White Poland Active ptb 20 Pos (SPT, BAL) Neg 4 11 (15 4) 11 (15 4) 106 (109 3) 99 (102 3) 7 22 M White Turkey Active ptb 20 Neg Neg 2 72 (72 0) 82 (82 0) 41 (49 8) 49 (57 8) 8 97 F White Germany Active ptb 18 Neg Pos (SPT) 1 23 (23 0) 41 (41 0) 47 (56 9) 49 (58 9) 9 75 M Asian Pakistan Active ptb 23 Neg Neg 2 34 (38 4) 1 (5 4) 12 (14 2) 7 (9 2) M Asian Pakistan Active ptb 20 Pos (BAL) Neg 1 9 (9 0) 30 (30 0) 26 (30 4) 70 (74 4) M Asian Pakistan Active ptb 23 Pos (BAL) Neg 1 70 (74 4) 106 (110 4) 6 (10 4) 14 (18 4) F Asian South Korea Active ptb 18 Pos (SPT) Neg 2 6 (6 0) 19 (19 0) 44 (57 13) 71 (84 13) M White Kazakhstan Former TB (1991) lung n.d. Neg Neg 3 6 (38 32) 17 (49 32) 4 (7 3) 4 (7 3) M White Turkey Septic embolism 0 Neg Neg 3 1 (1 0) n.d. 2 (2 0) n.d M White Poland Bronchiogenic carcinoma 0 Neg Neg 2 2 (3 1) n.d. 2 (4 2) n.d F White Germany COP 0 Neg Neg 1 6 (15 9) 4 (13 9) 1 (2 1) 0 (1 1) M White Germany Sarcoidosis 0 Neg Neg 2 0 (0 0) 1 (1 0) 2 (2 0) 3 (3 0) M White Germany COP 0 Neg Neg 1 1 (1.5 0) 0 (0 0) 0 (1 1) 0 (1 1) M White Germany Pneumonia 15 Neg Neg (119 1) 112 (113 1) 1 (1 0) 0 (0 0) M Asian Pakistan Former TB (2004) n.d. Neg Neg 1 2 (2 0) 6 (6 0) 2 (2 0) 1 (1 0) M White Germany Bronchiogenic carcinoma, 13 Neg Pos (BAL) 5 43 (43 0) 37 (37 0) 0 (2 2) 0 (2 2) former TB (1994) F White Germany Pneumonia 12 Neg Neg 1 0 (0 0) 1 (1 0) 0 (0 0) 0 (0 0) M White Tchetchenia Treatment for LTBI (2001) 22 Neg Neg 1 8 (8 0) n.d 1 (2 1) n.d F White Germany Rheumatoid arthritis 0 Neg Neg 1 1 (2 1) 1 (2 1) 0 (1 1) 2 (3 1) M White Germany Pneumonia 0 Neg Neg 2 1 (2 1) 1 (2 1) 2 (4 2) 2 (4 2) M White Kazakhstan Bronchiogenic carcinoma, 23 Neg Pos (BAL) 1 3 (3 0) 9 (9 0) 1 (1 0) 1 (1 0) former TB (2005) M White Germany COP 0 Neg Neg 2 0 (0 0) 0 (0 0) 0 (1 1) 1 (2 1) M White Germany Former M. kansasii 10 Neg Neg 1 0 (0 0) 0 (0 0) 1 (1 0) 1 (1 0) infection M White Germany Pneumonia 20 Neg Neg 1 6 (6 0) 6 (6 0) 0 (0 0) 0 (0 0) F White Romania Bronchiogenic carcinoma 17 Neg Neg 1 10 (11 1) 1 (2 1) 3 (3 0) 0 (0 0) F White Germany Pneumonia 0 Neg Neg 2 5 (5 0) 0 (0 0) 0 (0 0) 0 (0 0) M White Germany Sarcoidosis 0 Neg Neg 2 0 (0 0) 0 (0 0) 0 (1 1) 0 (1 1) F White Germany Sarcoidosis 0 Neg Neg 2 0 (1 1) 0 (1 1) 0 (3 5) 1 (6 5) M White Germany Sarcoidosis 0 Neg Neg 2 0 (0 0) 0 (0 0) 0 (0 0) 0 (0 0) M White Germany Pneumonia 0 Neg Neg 3 0 (0 0) 0 (0 0) 0 (3 6) 0 (1 6) M White Germany Former TB (2001) 0 Neg Neg 2 0 (0 1) 49 (50 1) 2 (6 4) 0 (4 4) F Asian China Former TB (2002) 14 Neg Neg 1 8 (8 0) 51 (51 0) 5 (5 0) 3 (3 0) Definition of abbreviations: BAL bronchoalveolar lavage; CFP-10 culture filtrate protein-10; COP cryptogenic organizing pneumonia; ESAT-6 early secretory antigenic target-6; F female; LTBI latent tuberculosis infection; M male; MTB Mycobacterium tuberculosis; NAT nucleic acid amplification technique; n.d. data not available; PBMCs peripheral blood mononuclear cells; ptb pulmonary tuberculosis; SPT sputum; TST tuberculin skin test. MTB culture was performed on sputum and BAL fluid of all patients. * Numbers represent net numbers of spot-forming cells per 200,000 PBMCs or BALMCs on IFN- ELISPOT; numbers in parentheses represent absolute spots per well minus spots in control wells. CFP-10 specific T cells compartmentalized in the lung versus blood than patients from the control group. However, when these ratios were compared with the raw data, the raw data better discriminated between patients with active TB and control subjects (data not shown). When instead of ESAT-6 and CFP-10 peptides, PPD was used as an antigen, results were similar but did not fully discriminate between patients with active ptb and control patients. In the control group, BAL specimens from seven patients were positive for PPD (Figure 3). Ten patients in the control group had positive ELISPOT results in the blood. Five of these patients had previously been treated for ptb (Years 1994, 2001, 2002, 2004, and 2005) and one patient had been treated for LTBI (Year 2001). Their PBMCs responded to at least one of the peptides (range, 0 43 spot-forming cells [sfc]/200,000 cells for ESAT-6; range, 6 51 sfc/200,000 cells for CFP-10). Four other patients in the control group, three with pneumonia and one with bronchogenic carcinoma, also had positive ELISPOT results for PBMCs (range, sfc/200,000 cells for ESAT-6; range, sfc/200,000 cells for CFP-10) and were considered to have LTBI. Numbers of ESAT-6, CFP-10, and PPD-specific spot-forming cells among BALMCs, but not among PBMCs, were significantly associated with ptb independent of age and sex (data not shown). There were no differences in the distribution of CD4,CD8, CD38,HLA-DR,CD4 CD45RO,orCD4 CD45RA Tcells from the blood or BAL among patients from both groups (data not shown). DISCUSSION MTB-specific IFN- release assays based on MTB RD1 peptides ESAT-6 and CFP-10 have been developed for commercial use

4 Jafari, Ernst, Kalsdorf, et al.: TB Diagnosis by BAL ELISPOT 1051 TABLE 2. COMPARISON OF PATIENTS WITH TUBERCULOSIS AND PATIENTS WITH PULMONARY INFILTRATES OF OTHER ORIGIN TB Non-TB p Value n NA Sex, M/F 10/2 19/ Age (yr), median (IQR) 31.1 ( ) 50.5 ( ) M. tuberculosis specific PCR, no. positive (%) 4/12 (33%) 2/25 (8%) 0.05 Induration of the tuberculin skin test (mm), median (IQR) 20.0 ( ) 0 (0 14.0) ESAT-6 positive cells/200,000 PBMCs, median (IQR) 17.0 ( ) 1.0 (0 6.0) CFP-10 positive cells/200,000 PBMCs, median (IQR) 24.5 ( ) 1.0 (0 13.0) ESAT-6 positive cells/200,000 BALMCs, median (IQR) 37.5 ( ) 0 (0 2.0) CFP-10 positive cells/200,000 BALMCs, median (IQR) 49.5 ( ) 0 (0 1.0) PPD-positive cells/200,000 PBMCs, median (IQR) 44.0 ( ) 15.0 ( ) PPD-positive cells/200,000 BALMCs, median (IQR) 80.5 ( ) 1.0 (0 8.0) Definition of abbreviations: IQR interquartile range; NA not applicable; PCR polymerase chain reaction; TB tuberculosis. All patients had three negative sputum smear results for acid-fast bacilli before enrollment. Numbers represent median values with interquartile ranges in parentheses. both as ELISPOT and ELISA for the diagnosis of TB and LTBI from blood. The ELISPOT assay has higher sensitivity and specificity (9, 15, 25, 33 41) for the diagnosis of TB compared with the TST. In contrast to the TST, the MTB-specific IFN- release assays are not influenced by prior BCG vaccination and have lower cross-reactivity to mycobacteria other than TB (15, 21, 42, 43). However, like the TST, MTB-specific IFN- release assays do not allow distinction between active TB and LTBI when performed on blood. Smear-negative TB is a common problem in clinical practice, where a clear and rapid distinction between active TB and LTBI has not been possible so far. In our hospital, 54% of patients with ptb confirmed by culture could not be identified by three consecutive sputum examinations for the presence of AFB. Moreover, the sensitivity of an MTB-specific polymerase chain reaction in culture-positive smear-negative ptb was only 64% (95% confidence interval, ) in our study (3 of 8 prospectively studied patients and 18 of 25 retrospectively studied patients), comparable to a sensitivity of 58 86%, which has been published by others (44, 45). In the diagnosis of MTB infection, the MTB-specific ELIS- POT assay (T-SPOT.TB) has a high diagnostic sensitivity and a low rate of indeterminate results when performed on PBMCs (46, 47). For this test, measured IFN- release can be directly related to the number of antigen-specific mononuclear cells in Figure 1. Induration diameters of tuberculin skin tests (TSTs) of patients with smear-negative pulmonary tuberculosis (TB; n 12, open circles) or patients with pulmonary infiltrates of other origin (n 25, solid triangles). Seven patients in the non-tb group had been treated for pulmonary TB in the past. a biological specimen. In TB, antigen-specific T cells clonally expand and are recruited to the sites of infection (27, 28). MTB antigen specific lymphocytes are compartmentalized in the lungs in healthy household contacts (48) and in patients with active ptb and on challenge produce helper T-cell type 1 cytokine host responses (49). In an experimental setting, helper T-cell type 1 like effector memory cell responses can be elicited in BALMCs after bronchoscopic challenge with PPD into a lung segment of healthy TST-positive volunteers (50, 51). Measurement of type 1 cytokine production by CD4 T cells in response to PPD in BAL fluid was shown to be highly sensitive and specific for the diagnosis of active TB (52). However, the analysis of RD-1 specific immune responses of mononuclear cells from the site of MTB infection may be more specific for the diagnosis of active TB than analysis of PPD responses. For example, Wilkinson and coworkers showed that ESAT-6 specific IFN- secreting T cells are concentrated in tuberculous pleural effusion and ascites and are absent in pleural effusions of other etiology (53). The clinical utility of this approach was demonstrated in the diagnosis of a patient with disseminated pleural TB and hairy cell leukemia (54). Although numbers of PPD-reactive BALMCs were much higher in patients with ptb than in control subjects, some patients with nontuberculous pulmonary infiltrates also had high numbers of PPD-specific IFN- releasing cells in the BAL fluid. The ELISPOT assay of BALMCs with ESAT-6 and CFP-10 peptides was therefore more specific for the diagnosis of ptb than was the ELISPOT with PPD peptide from BAL fluid, the MTB-specific ELISPOT performed on PBMCs, or the TST. We found 10 patients in the control group with positive IFN- responses to ESAT-6 and/or CFP-10 peptides in PBMCs. Five had a history of prior TB and one had received prior treatment for LTBI. The remaining four patients in the control group with positive IFN- responses to ESAT-6 and/or CFP-10 in the blood and not BAL fluid were suspected to be latently infected with MTB. In this study, we found that both ESAT-6 and CFP-10 peptide specific mononuclear cell responses were detectable in BALMCs only from patients with active ptb, whereas these responses were absent in patients with LTBI, in patients with a history of TB without current reactivation, or in patients with pulmonary infiltrates of other origin. By enumerating ESAT-6 and CFP- 10 specific BALMCs, patients with active TB could be fully distinguished from patients with pulmonary infiltrates of other origin.

5 1052 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL Figure 2. Concentration of early secretory antigenic target-6 (ESAT-6) and culture filtrate protein-10 (CFP-10) IFN- producing spot-forming cells (sfc) in peripheral blood mononuclear cells (PBMCs) or bronchoalveolar lavage mononuclear cells (BALMCs) of patients with smear-negative pulmonary TB (n 12, open and solid circles for ESAT-6 and CFP-10 peptides, respectively) or patients with nontuberculous pulmonary infiltrates (n 25; open and solid diamonds for ESAT-6 and CFP-10 peptides, respectively). The dashed line represents a cutoff of 5 sfc/200,000 cells. In contrast to ELISPOT performed on PBMCs, ELISPOT performed on BALMCs fully discriminates between patients with active pulmonary TB and patients with nontuberculous pulmonary infiltrates. All spots are documented after subtraction of spots in negative control. Bars represent median values. Thus, active ptb may be better diagnosed when organspecific immune responses with MTB-specific peptides are evaluated by ELISPOT. However, our study has several limitations. The proportion of male patients was higher and patients were younger in the TB group compared with the control group. Therefore, the influence of age or sex for MTB-specific immune responses by BALMCs cannot be excluded. Although the diagnosis of active ptb could not be verified by a positive MTB culture result from the sputum or the BAL fluid of four patients, the diagnosis of ptb in these cases was likely, given that all patients had positive TSTs and typical pulmonary infiltrates on chest CT suggesting active TB, and all four patients responded well to anti-tb therapy. All four patients also had positive ESAT-6 and CFP-10 specific ELISPOT on PBMCs. When a cutoff of five antigen-reactive cells per 200,000 BALMCs was used, the sensitivity and specificity of the MTB- specific ELISPOT with ESAT-6 and CFP-10 peptides were both 100% (95% confidence interval, ) in this small cohort. These values are much higher than the sensitivity and specificity values of sputum or BAL DNA amplification, but these data will need validation in larger studies, including countries with a high TB incidence. It also remains to be seen whether a BAL ELISPOT can be applied to patients with immunodeficiencies such as HIV infection, where lower numbers of BALMCs may be expected. If confirmed in larger cohorts, the findings of this study may potentially improve the diagnostic evaluation of smear-negative pulmonary tuberculosis in clinical settings, where bronchoscopy and ELISPOT techniques are available. We have shown for the first time that the diagnosis of smearnegative ptb can be established rapidly by enumeration of MTB-specific T cells from BAL fluid and that the MTB-specific ELISPOT, when applied to BAL fluid, may distinguish with high sensitivity and specificity between active ptb and LTBI. Figure 3. Concentration of purified protein derivate (PPD) specific IFN- producing spot-forming cells in PBMCs or BALMCs of patients with smear-negative pulmonary TB (n 12; open triangles) or patients with nontuberculous pulmonary infiltrates (n 25; solid triangles). The dashed line represents a cutoff of 5 sfc/200,000 cells. In contrast to ELISPOT performed on PBMCs and BALMCs with ESAT-6 and CFP-10 (see Figure 2), a PPD-based ELISPOT performed on PBMCs or BALMCs does not fully discriminate between patients with active pulmonary TB and patients with nontuberculous pulmonary infiltrates. All spots are documented after subtraction of spots in negative control. Bars represent median values.

6 Jafari, Ernst, Kalsdorf, et al.: TB Diagnosis by BAL ELISPOT 1053 Conflict of Interest Statement : C.J. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. M.E. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. B.K. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. U.G. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. R.D. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. D.K. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. K.M. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. A.L. is a named inventor on several patents related to T-cell diagnosis filed by the University of Oxford. Regulatory approval of ELISPOT has been undertaken by Oxford Immunotec, in which he is a shareholder and to which he acts as a scientific advisor. C.L. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. Acknowledgment : The authors thank Dr. Sabine Ruesch-Gerdes and Dr. Elvira Richter (National Reference Center for Mycobacteria, Borstel, Germany) for assistance and critical review of the manuscript, and Silke Lange (Dortmund, Germany) for statistical advice. References 1. World Health Organization. Global tuberculosis control: surveillance, planning, financing. Geneva, Switzerland: World Health Organization; Hanna BA, Ebrahimzadeh A, Elliott LB, Morgan MA, Novak SM, Rusch-Gerdes S, Acio M, Dunbar DF, Holmes TM, Rexer CH, et al. Multicenter evaluation of the BACTEC MGIT 960 system for recovery of mycobacteria. J Clin Microbiol 1999;37: Altmann D, Brodhun B, Haas W. Report on the epidemiology of tuberculosis for Berlin, Germany: Robert Koch Institute; American Thoracic Society, Centers for Disease Control and Prevention. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000;161: Pfyffer GE. [Ranking of the polymerase chain reaction (PCR) and of other amplification methods in the diagnosis of tuberculosis]. Pneumologie 2004;58: Arend SM, Geluk A, van Meijgaarden KE, van Dissel JT, Theisen M, Andersen P, Ottenhoff TH. Antigenic equivalence of human T-cell responses to Mycobacterium tuberculosis-specific RD1-encoded protein antigens ESAT-6 and culture filtrate protein 10 and to mixtures of synthetic peptides. Infect Immun 2000;68: Berthet FX, Rasmussen PB, Rosenkrands I, Andersen P, Gicquel B. A Mycobacterium tuberculosis operon encoding ESAT-6 and a novel low-molecular-mass culture filtrate protein (CFP-10). Microbiology 1998;144: Lalvani A, Nagvenkar P, Udwadia Z, Pathan AA, Wilkinson KA, Shastri JS, Ewer K, Hill AV, Mehta A, Rodrigues C. Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. J Infect Dis 2001;183: Lalvani A, Pathan AA, McShane H, Wilkinson RJ, Latif M, Conlon CP, Pasvol G, Hill AV. Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Am J Respir Crit Care Med 2001;163: Liebeschuetz S, Bamber S, Ewer K, Deeks J, Pathan AA, Lalvani A. Diagnosis of tuberculosis in South African children with a T-cell-based assay: a prospective cohort study. Lancet 2004;364: Ravn P, Munk ME, Andersen AB, Lundgren B, Lundgren JD, Nielsen LN, Kok-Jensen A, Andersen P, Weldingh K. Prospective evaluation of a whole-blood test using Mycobacterium tuberculosis-specific antigens ESAT-6 and CFP-10 for diagnosis of active tuberculosis. Clin Diagn Lab Immunol 2005;12: Kang YA, Lee HW, Yoon HI, Cho B, Han SK, Shim YS, Yim JJ. Discrepancy between the tuberculin skin test and the whole-blood interferon assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA 2005;293: Munk ME, Arend SM, Brock I, Ottenhoff TH, Andersen P. Use of ESAT-6 and CFP-10 antigens for diagnosis of extrapulmonary tuberculosis. J Infect Dis 2001;183: Chapman AL, Munkanta M, Wilkinson KA, Pathan AA, Ewer K, Ayles H, Reece WH, Mwinga A, Godfrey-Faussett P, Lalvani A. Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells. AIDS 2002;16: Brock I, Weldingh K, Lillebaek T, Follmann F, Andersen P. Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. Am J Respir Crit Care Med 2004;170: Brock I, Munk ME, Kok-Jensen A, Andersen P. Performance of whole blood IFN- test for tuberculosis diagnosis based on PPD or the specific antigens ESAT-6 and CFP-10. Int J Tuberc Lung Dis 2001;5: Meier T, Eulenbruch HP, Wrighton-Smith P, Enders G, Regnath T. Sensitivity of a new commercial enzyme-linked immunospot assay (T SPOT-TB) for diagnosis of tuberculosis in clinical practice. Eur J Clin Microbiol Infect Dis 2005;24: Mori T, Sakatani M, Yamagishi F, Takashima T, Kawabe Y, Nagao K, Shigeto E, Harada N, Mitarai S, Okada M, et al. Specific detection of tuberculosis infection: an interferon- -based assay using new antigens. Am J Respir Crit Care Med 2004;170: Anderson ST, Williams AJ, Brown JR, Newton SM, Simsova M, Nicol MP, Sebo P, Levin M, Wilkinson RJ, Wilkinson KA. Transmission of Mycobacterium tuberculosis undetected by tuberculin skin testing. Am J Respir Crit Care Med 2006;173: Richeldi L, Ewer K, Losi M, Bergamini BM, Roversi P, Deeks J, Fabbri LM, Lalvani A. T cell-based tracking of multidrug resistant tuberculosis infection after brief exposure. Am J Respir Crit Care Med 2004; 170: Diel R, Ernst M, Doscher G, Visuri-Karbe L, Greinert U, Niemann S, Nienhaus A, Lange C. Avoiding the effect of BCG vaccination in detecting MTB infection with a blood test. Eur Respir J 2006;28: Lalvani A, Pathan AA, Durkan H, Wilkinson KA, Whelan A, Deeks JJ, Reece WH, Latif M, Pasvol G, Hill AV. Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet 2001;357: Ewer K, Deeks J, Alvarez L, Bryant G, Waller S, Andersen P, Monk P, Lalvani A. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 2003;361: Dheda K, Rook G, Zumla A. Peripheral T cell interferon- responses and latent tuberculosis. Am J Respir Crit Care Med 2004;170:97 98; author reply Pai M, Riley LW, Colford JM Jr. Interferon- assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 2004;4: Westermann J, Pabst R. Distribution of lymphocyte subsets and natural killer cells in the human body. Clin Investig 1992;70: Barnes PF, Lu S, Abrams JS, Wang E, Yamamura M, Modlin RL. Cytokine production at the site of disease in human tuberculosis. Infect Immun 1993;61: Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001; 19: Charoenratanakul S, Dejsomritrutai W, Chaiprasert A. Diagnostic role of fiberoptic bronchoscopy in suspected smear negative pulmonary tuberculosis. Respir Med 1995;89: de Gracia J, Curull V, Vidal R, Riba A, Orriols R, Martin N, Morell F. Diagnostic value of bronchoalveolar lavage in suspected pulmonary tuberculosis. Chest 1988;93: Haussinger K, Ballin A, Becker HD, Bolcskei P, Dierkesmann R, Dittrich I, Frank W, Freitag L, Gottschall R, Guschall WR, et al. [Recommendations for quality standards in bronchoscopy]. Pneumologie 2004;58: Sokal JE. Editorial: measurement of delayed skin-test responses. N Engl JMed1975;293: Johnson PD, Stuart RL, Grayson ML, Olden D, Clancy A, Ravn P, Andersen P, Britton WJ, Rothel JS. Tuberculin-purified protein derivative, MPT-64, and ESAT-6 stimulated interferon responses in medical students before and after Mycobacterium bovis BCG vaccination and in patients with tuberculosis. Clin Diagn Lab Immunol 1999;6: Lein AD, von Reyn CF, Ravn P, Horsburgh CR Jr, Alexander LN, Andersen P. Cellular immune responses to ESAT-6 discriminate between patients with pulmonary disease due to Mycobacterium avium complex and those with pulmonary disease due to Mycobacterium tuberculosis. Clin Diagn Lab Immunol 1999;6: Pathan AA, Wilkinson KA, Klenerman P, McShane H, Davidson RN, Pasvol G, Hill AV, Lalvani A. Direct ex vivo analysis of antigenspecific IFN- secreting CD4 T cells in Mycobacterium tuberculosisinfected individuals: associations with clinical disease state and effect of treatment. J Immunol 2001;167: Ravn P, Demissie A, Eguale T, Wondwosson H, Lein D, Amoudy HA, Mustafa AS, Jensen AK, Holm A, Rosenkrands I, et al. Human T cell

7 1054 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL responses to the ESAT-6 antigen from Mycobacterium tuberculosis. J Infect Dis 1999;179: Rolinck-Werninghaus C, Magdorf K, Stark K, Lyashchenko K, Gennaro ML, Colangeli R, Doherty TM, Andersen P, Plum G, Herz U, et al. The potential of recombinant antigens ESAT-6, MPT63 and mig for specific discrimination of Mycobacterium tuberculosis and M. avium infection. Eur J Pediatr 2003;162: Ulrichs T, Anding P, Porcelli S, Kaufmann SH, Munk ME. Increased numbers of ESAT-6 and purified protein derivative specific interferon producing cells in subclinical and active tuberculosis infection. Infect Immun 2000;68: Vincenti D, Carrara S, De Mori P, Pucillo LP, Petrosillo N, Palmieri F, Armignacco O, Ippolito G, Girardi E, Amicosante M, et al. Identification of early secretory antigen target-6 epitopes for the immunodiagnosis of active tuberculosis. Mol Med 2003;9: Rothel JS, Andersen P. Diagnosis of latent Mycobacterium tuberculosis infection: is the demise of the Mantoux test imminent? Expert Rev Anti Infect Ther 2005;3: Dheda K, Udwadia ZF, Huggett JF, Johnson MA, Rook GA. Utility of the antigen-specific interferon- assay for the management of tuberculosis. Curr Opin Pulm Med 2005;11: Zellweger JP, Zellweger A, Ansermet S, de Senarclens B, Wrighton- Smith P. Contact tracing using a new T-cell based test: better correlation with tuberculosis exposure than the tuberculin skin test. Int J Tuberc Lung Dis 2005;9: Shams H, Weis SE, Klucar P, Lalvani A, Moonan PK, Pogoda JM, Ewer K, Barnes PF. Enzyme-linked immunospot and tuberculin skin testing to detect latent tuberculosis infection. Am J Respir Crit Care Med 2005;172: Rusch-Gerdes S, Richter E. Clinical evaluation of the semiautomated BD ProbeTec ET system for the detection of Mycobacterium tuberculosis in respiratory and nonrespiratory specimens. Diagn Microbiol Infect Dis 2004;48: Tueller C, Chhajed PN, Buitrago-Tellez C, Frei R, Frey M, Tamm M. Value of smear and PCR in bronchoalveolar lavage fluid in culture positive pulmonary tuberculosis. Eur Respir J 2005;26: Lee JY, Choi HJ, Park IN, Hong SB, Oh YM, Lim CM, Lee SD, Koh Y, Kim WS, Kim DS, et al. Comparison of two commercial interferon assays for diagnosing Mycobacterium tuberculosis infection. Eur Respir J 2006;28: Ferrara G, Losi M, D Amico R, Roversi P, Piro R, Meacci M, Meccugni B, Dori IM, Andreani A, Bergamini BM, et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 2006;367: Schwander SK, Torres M, Carranza CC, Escobedo D, Tary-Lehmann M, Anderson P, Toossi Z, Ellner JJ, Rich EA, Sada E. Pulmonary mononuclear cell responses to antigens of Mycobacterium tuberculosis in healthy household contacts of patients with active tuberculosis and healthy controls from the community. J Immunol 2000;165: Schwander SK, Torres M, Sada E, Carranza C, Ramos E, Tary-Lehmann M, Wallis RS, Sierra J, Rich EA. Enhanced responses to Mycobacterium tuberculosis antigens by human alveolar lymphocytes during active pulmonary tuberculosis. J Infect Dis 1998;178: Walrath J, Zukowski L, Krywiak A, Silver RF. Resident Th1-like effector memory cells in pulmonary recall responses to Mycobacterium tuberculosis. Am J Respir Cell Mol Biol 2005;33: Silver RF, Zukowski L, Kotake S, Li Q, Pozuelo F, Krywiak A, Larkin R. Recruitment of antigen-specific Th1-like responses to the human lung following bronchoscopic segmental challenge with purified protein derivative of Mycobacterium tuberculosis. Am J Respir Cell Mol Biol 2003;29: Barry SM, Lipman MC, Bannister B, Johnson MA, Janossy G. Purified protein derivative activated type 1 cytokine-producing CD4 T lymphocytes in the lung: a characteristic feature of active pulmonary and nonpulmonary tuberculosis. J Infect Dis 2003;187: Wilkinson KA, Wilkinson RJ, Pathan A, Ewer K, Prakash M, Klenerman P, Maskell N, Davies R, Pasvol G, Lalvani A. Ex vivo characterization of early secretory antigenic target 6 specific T cells at sites of active disease in pleural tuberculosis. Clin Infect Dis 2005;40: Richeldi L, Luppi M, Losi M, Luppi F, Potenza L, Roversi P, Cerri S, Millington KA, Ewer K, Fabbri LM, et al. Diagnosis of occult tuberculosis in hematological malignancy by enumeration of antigen-specific T cells. Leukemia 2006;20: